Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.43 |
| ▸ | NQO2 | P16083 | 6/20 | 0.43 |
| ▸ | VCP | P55072 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 3/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP1 | P63208 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5202994 | 0.87 | CKS1B (0.39) | CKS1BSKP1SKP2MMP12 | |
| SCHEMBL5205206 | 0.87 | CKS1B (0.49) | VCPCKS1BSKP1SKP2 | |
| SCHEMBL5202973 | 0.80 | VCP (0.45) | VCPCKS1BSKP1SKP2 | |
| SCHEMBL5203657 | 0.80 | CKS1B (0.41) | VCPCKS1BSKP1SKP2 | |
| SCHEMBL90867 | 0.73 | RIPK2 (0.37) | GSK3B | |
| SCHEMBL6168935 | 0.73 | HTR2B (0.48) | — | |
| SCHEMBL5205247 | 0.72 | VCP (0.45) | VCP | |
| SCHEMBL311158 | 0.72 | KMT2A (0.56) | — | |
| SCHEMBL5207569 | 0.69 | KMT2A (0.41) | VCPCKS1BSKP1SKP2 | |
| SCHEMBL9259393 | 0.69 | ITGB3 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1306085-B1 | 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor | NEUROGEN CORP (US) | 2007-02-14 | — | — | EP | claimed |
| US-7034034-B2 | Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives | NEUROGEN CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| WO-2003104255-A2 | SUBSTITUTED 2-CYCLOHEXYL-4-PHENYL-1H-IMIDAZOLE DERIVATIVES | NEUROGEN CORPORATION (US) | 2003-12-18 | — | — | WO | claimed |
| US-20030144290-A1 | Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives | NEUROGEN CORPORATION | 2003-07-31 | — | — | US | claimed |
| EP-1306085-A1 | 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor | Neurogen Corporation (US) | 2003-05-02 | — | — | EP | claimed |
| EP-1306085-B1 | 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor | NEUROGEN CORP (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7034034-B2 | Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives | NEUROGEN CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| WO-2003104255-A2 | SUBSTITUTED 2-CYCLOHEXYL-4-PHENYL-1H-IMIDAZOLE DERIVATIVES | NEUROGEN CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030144290-A1 | Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives | NEUROGEN CORPORATION | 2003-07-31 | — | — | US | disclosed |
| EP-1306085-A1 | 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor | Neurogen Corporation (US) | 2003-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144290-A1 | Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives | NPY5R, NPY4R, NPY1R | MTNR1A 793/4885MTNR1B 396/4885NQO2 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.